Clinical trial
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone…
NCT00411528 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00411528 |
|---|---|
| Title | Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer |
| Official title | A Randomized Multicenter Phase II Trial of Patupilone (EPO906) Plus Prednisone Versus Docetaxel Plus Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Hormone Refractory Prostate Cancer |
| Intervention type | Drug |
| Interventions | Patupilone, prednisone, docetaxel |
| Enrollment | 185 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | Dec 14, 2006 |
| Last update posted | Dec 17, 2020 |
| Countries | Australia, Belgium, France, Germany, Italy, Singapore, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: